PatentVest

Interesting perspective, Saman Hagh Gooie. CereGate was included in our report. We would welcome a conversation about how to measure IP strength and build a meaningful portfolio. Let’s keep the conversation going. We are tagging our Chief IP Officer, Will R..

Great points, Ryan Field—and we appreciate you jumping into the conversation. We agree: the definition of a brain-computer interface is evolving. Implantable vs. non-implantable. Passive vs. active. Diagnostic vs. therapeutic. The edges are blurry—and the best companies are the ones pushing those edges. This particular report focused on direct-interfacing BCIs—invasive or minimally invasive systems that enable active brain-to-device interaction (movement, communication, stimulation). That said, we did highlight a few passive BCIs—non-invasive systems interpreting neural activity to inform or adapt external systems. But let’s be clear: Measurement ≠ interface. Not every neurotech platform is a BCI company. And not every patent portfolio translates to strategic control. We classified companies based on what they are actively deploying and claiming today—not just what their patents suggest they might do. 140+ granted patents is impressive. But as we said in the report: “A patent ≠ a strategy. The leaders file to shape markets.” So the real question is: Is Kernel leading the next wave of passive BCIs—or redefining what brain imaging can do? We’d love to learn more. We’re already working on a broader follow-up analysis of passive BCIs and neurotech platforms, powered by our proprietary global patent database. We look forward to including Kernel in that next wave. Let’s keep the conversation going. We are tagging our Chief IP Officer, Will R..

The #BCI Startup Everyone’s Watching Might Not Be the One That Wins. Everyone’s talking about brain-computer interfaces (BCIs). But as these technologies move from labs into clinics, the question isn’t whether BCI will be real—it’s: Who will own this technology? With millions affected by paralysis, epilepsy, and treatment-resistant depression, BCIs are no longer theoretical—they’re laying the foundation for a new model of neurological care. But in this emerging $400B market, breakthrough technology isn’t enough. The companies that win won’t just build great tech—they’ll align their clinical path, regulatory milestones, and, most importantly, their IP from day one. To understand who’s actually leading—and who’s at risk—we conducted two foundational analyses: 1. Company Benchmarking: We analyzed the platforms, IP portfolios, and strategic positions of key players: Synchron, Neuralink, Blackrock Neurotech, Precision Neuroscience, INBRAIN Neuroelectronics, Paradromics, Axoft, Motif Neurotech, and Science Corp. The result: a clear view of who’s building defensible positions—and who’s just hoping to. 2. IP Landscape Mapping: We examined 2,160+ patent families from 664 organizations, including startups and major universities. The data revealed where foundational IP is already claimed, where white space remains, and which companies are filing to shape the future—not follow it. Inside the report, we reveal who owns the critical IP, where real innovation is happening, and how IP strategy—not just science—is determining which companies will win. Access the report here: https://lnkd.in/gXeqK5Wp #BCI #Neurotech #PatentStrategy #DeepTech #IPStrategy #Synchron #Neuralink #MedTech #PatentVestPulse #BrainComputerInterface

The New AI Patent Race: Is China Leading the $431B Data Center Gold Rush? As #AI reshapes industries, data centers are evolving to handle the explosive growth of AI workloads, with enterprise data generation projected to reach 1.2 million exabytes by 2025. The data center market is on track to hit $431.43 billion by 2030, but who will control the infrastructure powering AI’s future? #Patent filings reveal a clear trend—#China dominates AI data center patents, accounting for 77 percent of all filings globally. Intel Corporation leads in global publications, but State Grid Corporation of China, Chongqing University, Nanjing University, Huawei, and the Chinese Academy of Sciences are aggressively securing the foundational IP needed to define AI infrastructure standards. Other key players shaping AI-driven data centers include Samsung Electronics, Lumen Technologies, Verizon, and IBM, each expanding their portfolios in AI-specific #semiconductors, high-speed interconnects, and energy-efficient cooling.   The real question: Is the U.S. falling behind in the AI-driven data center patent race?    The latest PatentVest Pulse Report explores the patent landscape shaping AI data centers, highlighting who is winning, what technologies are driving the race, and where companies must focus to compete.   Read the full report here: https://lnkd.in/gpVg7Cpt #DataCenter #Patents #IPStrategy #DeepTech #AIInfrastructure #China #Innovation #Semiconductors NVIDIA

As #diabetes continues to affect millions worldwide, with projections to rise to 783 million by 2045, the need for real-time glucose monitoring has never been more critical. Continuous Glucose Monitors (CGMs) are helping patients actively manage their condition by providing constant, real-time insights into their glucose levels. To better understand the dynamics of the Continuous Glucose Monitoring (#CGM) market, we developed an exclusive IP landscape analysis, unveiling the latest technological trends and identifying key players, including emerging startups pioneering innovative solutions. Our latest PatentVest Pulse report provides actionable insights into the rapidly expanding CGM space, covering critical market shifts, technological advancements, and the key players shaping the future of diabetes management. In this report, we explore the role of technological advancements that are making diabetes care more accessible and effective. We also examine how market dynamics—particularly the rise of OTC CGM products—are transforming the landscape of diabetes care. Additionally, the report highlights the intellectual property strategies employed by companies like Dexcom, Abbott, Medtronic, and Roche to secure leadership positions in the market. Read the full report today to uncover the key trends and competitive insights shaping the future of CGM: https://lnkd.in/g-iCDp2g #Diabetes #HealthcareInnovation #CGM #IntellectualProperty #Dexcom #Abbott #Medtronic #Roche #continuousglucosemonitor

Exciting News in Healthcare Innovation! PatentVest's latest whitepaper explores innovations in MASH diagnostics. PatentVest, the forefront of IP intelligence and law, has unveiled a new whitepaper shedding light on advancements in Metabolic-Associated Steatohepatitis (MASH) biomarkers and Point of Care (PoC) kits for enhanced diagnostics. Delving into the dynamic landscape of MASH technologies, the whitepaper offers strategic guidance on leveraging innovation, collaboration, and intellectual property protection for a competitive edge. Why should stakeholders look to this Whitepaper to navigate this complex and rapidly evolving landscape? PatentVest reveals promising patent opportunities in Biomarkers MASH and Artificial Intelligence Mark-up Language (AIML) fields; from non-invasive diagnostic tools to personalized disease management strategies, the whitepaper underscores key areas ripe for patent protection and industry growth. Understanding the existing patent landscape offers insights into new patenting spaces not already occupied by existing intellectual property rights. Companies and researchers that understand their IP landscapes can strategically focus their research and development and product development efforts and position themselves to capitalize on emerging opportunities in the Biomarkers MASH and Kits & PoC AIML technologies market. New patenting spaces represent potential avenues for innovation and intellectual property protection, helping companies and researchers establish a competitive edge in these rapidly evolving fields. For example, the discovery and validation of new biomarkers specific to MASH could lead to the development of innovative diagnostic tools, creating opportunities for patent protection in this space. Several notable patent applications have been published in these spaces, highlighting the innovative work being done by various companies and research institutions. PatentVest identifies key patent applications. Unlock the full potential of MASH diagnostics with PatentVest's insightful analysis! Click on the link below to stay ahead in the evolving landscape of healthcare innovation. https://lnkd.in/grmCakTG #HealthcareInnovation #MASHDiagnostics #PatentVest

PatentVest Pulse: Shaping the Future of Cardiac Health through Technology.   According to the data presented in this report, the portable ECG technology space has seen a 56% increase in global patent publications over the last five years, signaling a growing interest in the cardiac monitoring market, which is expected to grow to $3 billion per year by 2029, according to Statista.   This report shares insights into IP publication trends and the competitive landscape in the portable cardiac health technology space. It covers how portable ECG solutions can now detect arrhythmias and myocardial infarction by leveraging artificial intelligence and how 24/7 remote monitoring is now possible using smartphones and telehealth platforms.   This shift towards remote, patient-centric monitoring has the potential to revolutionize cardiac care, significantly reducing hospital readmissions and improving outcomes.   Click on the link below to read the full report and learn more about how these technologies will help save lives. https://lnkd.in/g3xDYFB8   The insights and analysis presented in this report were derived from IP Research work performed for HeartBeam, an active client of our firm. Our affiliated company, MDB Capital, has performed services for and owns an equity interest in HeartBeam. #Cardiology #HealthcareInnovation #Wearables #MedTech #ECG #Telehealth #MedicalDevices #patents